Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| HURA | 8-K | neutral | 2/10 | TuHURA Biosciences drew an additional $650,000 under its existing $50 million revolving credit facility with Parkview Ho | Oct 16, 2026 |
| PMCB | 8-K | bearish | 5/10 | PharmaCyte Biotech dismissed its auditor, CBIZ CPAs, and engaged Grassi & Co. as its new independent registered public a | Oct 16, 2026 |
| MDCX | 8-K | neutral | 3/10 | Medicus Pharma Ltd. filed an 8-K reporting a 1-for-50 reverse stock split (share consolidation) effective October 12, 20 | Oct 16, 2026 |
| ALEC | 8-K | bearish | 7/10 | Alector priced a dilutive underwritten offering of 36.6M shares at $2.05/share, raising ~$75M in gross proceeds. The off | Oct 16, 2026 |
| CALC | 8-K | bearish | 5/10 | CFO Stephen Bardin resigned effective after the Q3 2026 10-Q filing to pursue another opportunity, with no disagreement | Oct 16, 2026 |
| TCRX | 8-K | neutral | 2/10 | Two board members, Garry Nicholson and Gabriela Gruia, M.D., resigned from TScan Therapeutics' board effective October 1 | Oct 16, 2026 |
| TOMZ | 8-K | neutral | 2/10 | TOMI Environmental Solutions appointed Niroshan Srirathan as permanent CFO, effective October 11, 2026, after he served | Oct 16, 2026 |
| OCUL | 8-K | neutral | 2/10 | Chief Strategy Officer Sanjay Nayak resigned effective October 16, 2026 to become CEO of a private company. The departur | Oct 16, 2026 |
| QUCY | 8-K | neutral | 2/10 | Quantum Cyber N.V. appointed retired Major General Alberto C. Rosende as an independent director and committee member, e | Oct 16, 2026 |
| AIMD | 8-K | neutral | 2/10 | Ainos, Inc. filed an 8-K on October 14, 2026, adopting a classified board structure via Second Amended and Restated Byla | Oct 16, 2026 |
| AIBT | 8-K | neutral | 4/10 | Aibotics completed the acquisition of PlayJamaica's NovaCore Labs robotics, drone, AI, and mapping assets for $225,000 i | Oct 16, 2026 |
| BGMS | 8-K | neutral | 2/10 | Bio Green Med Solution, Inc. declared a quarterly cash dividend of $0.15 per share on its 6% Convertible Exchangeable Pr | Oct 16, 2026 |
| VIVS | 8-K | bearish | 5/10 | VivoSim Labs' wholly-owned subsidiary Organovo, Inc. amended its lease to reduce office space by vacating Suite 202 (2,8 | Oct 16, 2026 |
| MAZE | 8-K | neutral | 4/10 | Maze Therapeutics entered into an exchange agreement with Frazier Life Sciences funds to exchange 2,776,007 shares of co | Oct 16, 2026 |
| MBRX | 8-K | neutral | 3/10 | Moleculin Biotech filed an 8-K on October 16, 2026, to furnish a corporate investor presentation (Exhibit 99.1) posted o | Oct 16, 2026 |
| ERAS | 8-K | neutral | 2/10 | Erasca announced the termination of COO Nicholas Chetwyn, Ph.D., effective November 2, 2026, as part of a leadership rea | Oct 16, 2026 |
| EBS | 8-K | neutral | 3/10 | Emergent BioSolutions announced that CFO Richard Lindahl will retire effective December 31, 2026, and will serve as an a | Oct 16, 2026 |
| IRWD | 8-K | neutral | 3/10 | Ironwood Pharmaceuticals announced a planned CEO transition: current CEO Thomas McCourt will retire effective December 3 | Oct 16, 2026 |
| RGNX | 8-K | neutral | 2/10 | Director Kenneth T. Mills resigned from the board effective October 21, 2026, to focus on his new CEO role at another co | Oct 16, 2026 |
| ENSC | 8-K/A | bearish | 7/10 | Ensysce Biosciences filed an amended 8-K (8-K/A) providing unaudited pro forma financial information for its August 5, 2 | Oct 15, 2026 |
| SGMOQ | 8-K | bearish | 7/10 | Sangamo Therapeutics filed its Chapter 11 monthly operating report for August 2026, showing a net loss of $14.4 million | Oct 15, 2026 |
| ERNA | 8-K | neutral | 2/10 | Ernexa Therapeutics Inc. filed an 8-K on October 15, 2026, disclosing that it made an investor presentation available. T | Oct 15, 2026 |
| IRD | 8-K | bullish | 6/10 | Opus Genetics presented positive interim clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina | Oct 15, 2026 |
| BHVN | 8-K | bullish | 7/10 | Biohaven entered a strategic licensing agreement with Ono Pharmaceutical for its MoDE pan IgG degrader portfolio (BHV-13 | Oct 15, 2026 |
| ATNM | 8-K | neutral | 3/10 | Actinium Pharmaceuticals appointed Matt David, M.D. as CFO, effective October 14, 2026. Dr. David brings extensive bioph | Oct 15, 2026 |
| OLMA | 8-K | neutral | 2/10 | Olema Pharmaceuticals disclosed the resignation of board member Dr. Gorjan Hrustanovic, effective October 14, 2026, who | Oct 15, 2026 |
| BMRA | 8-K | neutral | 2/10 | Board member David Moatazedi will not stand for re-election at Biomerica's 2026 Annual Meeting on December 11, 2026, and | Oct 15, 2026 |
| ALXO | 8-K | mixed | 6/10 | ALX Oncology entered into exchange agreements with major stockholders (Blackstone, RA Capital, venBio) to surrender 13,3 | Oct 15, 2026 |
| NTHI | 8-K | neutral | 3/10 | NeOnc Technologies announced the resignation of director Dr. Steven Giannotta and the appointment of Ali Alabedin, Head | Oct 15, 2026 |
| TRAX | 8-K | bearish | 6/10 | First Tracks Biotherapeutics entered into a securities purchase agreement to sell 6,106,870 shares of common stock at $3 | Oct 15, 2026 |